Faron Pharmaceuticals Oy (LON:FARN) Stock Price Down 5.3% - Should You Sell?

Key Points

• Faron Pharmaceuticals Oy's stock decreased by 5.3% on Thursday, trading between GBX 180 ($2.38) and GBX 186.50 ($2.46), with a significant drop in trading volume.
• The company has a market capitalization of £250.38 million and a troubling price-to-earnings ratio of -4.99, indicating potential financial struggles.
• Insider Markku Jalkanen sold 600,000 shares at an average price of GBX 310 ($4.10), reflecting a substantial insider transaction amidst the stock decline.

Shares of Faron Pharmaceuticals Oy (LON:FARN - ) were down 5.3% on Thursday . The stock traded as low as GBX 180 ($2.38) and last traded at GBX 186.50 ($2.46). Approximately 13,146 shares changed hands during mid-day trading, a decline of 63% from the average daily volume of 35,549 shares. The stock had previously closed at GBX 197 ($2.60).

Faron Pharmaceuticals Oy Price Performance

The firm has a market capitalization of £250.38 million, a price-to-earnings ratio of -4.99 and a beta of 0.36. The company has a fifty day moving average price of GBX 214.56 and a two-hundred day moving average price of GBX 201.05. The company has a quick ratio of 1.09, a current ratio of 1.45 and a debt-to-equity ratio of 922.55.

Insider Buying and Selling at Faron Pharmaceuticals Oy

In related news, insider Markku Jalkanen sold 600,000 shares of the stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of GBX 310 ($4.10), for a total transaction of £1,860,000 ($2,457,067.37). Insiders own 31.82% of the company's stock.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.